Last reviewed · How we verify
combination with somatostatin analogue octreotide
combination with somatostatin analogue octreotide is a Somatostatin analogue Small molecule drug developed by Ludwig-Maximilians - University of Munich. It is currently FDA-approved for Neuroendocrine tumors (carcinoid tumors, gastroenteropancreatic neuroendocrine tumors), Acromegaly, Variceal bleeding in portal hypertension. Also known as: Octreotide: Sandostatin 100µg: MA number 29423.01.00.
Octreotide is a somatostatin analogue that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors.
Octreotide is a somatostatin analogue that binds to somatostatin receptors to inhibit the secretion of various hormones and growth factors. Used for Neuroendocrine tumors (carcinoid tumors, gastroenteropancreatic neuroendocrine tumors), Acromegaly, Variceal bleeding in portal hypertension.
At a glance
| Generic name | combination with somatostatin analogue octreotide |
|---|---|
| Also known as | Octreotide: Sandostatin 100µg: MA number 29423.01.00 |
| Sponsor | Ludwig-Maximilians - University of Munich |
| Drug class | Somatostatin analogue |
| Target | Somatostatin receptors (SSTR2, SSTR5) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Octreotide mimics the action of endogenous somatostatin by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells and tumors. This binding suppresses the release of growth hormone, insulin, glucagon, and other hormones, and also has direct antiproliferative effects on neuroendocrine tumor cells. When used in combination therapy, it may enhance therapeutic efficacy by reducing hormone-driven tumor growth and associated symptoms.
Approved indications
- Neuroendocrine tumors (carcinoid tumors, gastroenteropancreatic neuroendocrine tumors)
- Acromegaly
- Variceal bleeding in portal hypertension
Common side effects
- Hyperglycemia
- Abdominal pain
- Diarrhea
- Nausea
- Gallstone formation (cholelithiasis)
- Injection site reactions
Key clinical trials
- A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors (PHASE2)
- Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) (EARLY_PHASE1)
- Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly (PHASE3)
- Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly (PHASE4)
- Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors (PHASE3)
- Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors (PHASE2)
- Acute Application of Pegvisomant and Octreotide in Acromegaly (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- combination with somatostatin analogue octreotide CI brief — competitive landscape report
- combination with somatostatin analogue octreotide updates RSS · CI watch RSS
- Ludwig-Maximilians - University of Munich portfolio CI
Frequently asked questions about combination with somatostatin analogue octreotide
What is combination with somatostatin analogue octreotide?
How does combination with somatostatin analogue octreotide work?
What is combination with somatostatin analogue octreotide used for?
Who makes combination with somatostatin analogue octreotide?
Is combination with somatostatin analogue octreotide also known as anything else?
What drug class is combination with somatostatin analogue octreotide in?
What development phase is combination with somatostatin analogue octreotide in?
What are the side effects of combination with somatostatin analogue octreotide?
What does combination with somatostatin analogue octreotide target?
Related
- Drug class: All Somatostatin analogue drugs
- Target: All drugs targeting Somatostatin receptors (SSTR2, SSTR5)
- Manufacturer: Ludwig-Maximilians - University of Munich — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Neuroendocrine tumors (carcinoid tumors, gastroenteropancreatic neuroendocrine tumors)
- Indication: Drugs for Acromegaly
- Indication: Drugs for Variceal bleeding in portal hypertension
- Also known as: Octreotide: Sandostatin 100µg: MA number 29423.01.00
- Compare: combination with somatostatin analogue octreotide vs similar drugs
- Pricing: combination with somatostatin analogue octreotide cost, discount & access